



11-03-06

PATENT

IPU

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-005-D1CO)

In re Application of:

Irwin Braude

Serial No.: 10/784,413

Filing Date: February 23, 2004

For: Methods for Anti-Tumor Therapy

)  
)  
)  
)  
)  
)  
)  
)

Group Art Unit: 1614

Examiner: Anderson

Confirmation No. 1863

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

1. In regard to the above-mentioned application we are transmitting herewith the attached:
  - a) Transmittal Letter
  - b) Response to Office Action mailed May 9, 2006 (1 sheet);
  - c) Petition for 5-month extension of time (1 sheet);
  - d) Return receipt postcard
2. With respect to fees:
  - a) Enclosed please find a check in the amount of **\$1,080.00** for the Small Entity Five (5) month extension fee.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in a box addressed to: PO Box 1450, Alexandria, VA 22313-1450, on this 1<sup>st</sup> day of **November, 2006**. Express Mail No. **EV839376899US**.

Respectfully submitted,

David S. Harper, Ph.D.  
Registration No. 42,636



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
(Case No. 99-005-D1CO)

In re Application of:	)	
	)	
Irwin Braude	)	
	)	Group Art Unit: 1614
Serial No.: 10/784,413	)	
	)	Examiner: Anderson
Filing Date: February 23, 2004	)	
	)	Confirmation No. 1863
For: Methods for Anti-Tumor Therapy	)	

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


**RESPONSE TO THE OFFICE ACTION MAILED MAY 9, 2006**

Dear Sir:

In response to the office action mailed May 9, 2006, Applicant hereby elects N-(4-chlorophenyl)(3-[[[4-chlorophenyl)sulfonyl]amino}(2-naphthyl)carboxamide (Compound 5; see page 16 lines 1-4 of the specification) as the species to which the claims will be restricted if no other generic claim is finally held allowable. It is believed that each of pending claims 1-16 read on the elected species. As noted in the office action, upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all of the limitations of an allowable generic claim. If the Examiner has any questions, please contact the below signed Attorney at (312) 913-2106.

Date: 11/1/06

Respectfully submitted,

  
\_\_\_\_\_  
David S. Harper  
Registration No. 42,636